Heal Capital led the financing for the London-based developer of real-time hyperspectral imaging for surgery. Angelini Ventures, IP Group and Daycrest also participated. This round included follow-on investment from existing investors Heran partners, Redalpine, LifeX Ventures and Zeiss Ventures.
The company plans to use its latest cash infusion to accelerate the commercial deployment of its Hyperspectral Intelligence platform. It hopes to expand clinical adoption and advance development of next-generation hyperspectral sensing technology in partnership with Imec.
Hypervision aims to address fundamental limitations in visual assessments that guide critical intraoperative decisions. It says its hyperspectral imaging platform for surgery delivers quantitative tissue insights beyond human vision. The technology combines proprietary on-chip spectral sensing, patented AI analytics and a cloud-scalable architecture. This combination delivers real-time, data-driven support in surgical imaging.
The company says its architecture creates a scalable intelligence layer for surgical systems across open, minimally invasive, robotic and microscopic platforms. Hypersnap, its first commercial surgical system, is built on cloud computing giant Nvidia’s IGX platform. It has FDA clearance and approval in the UK for minimally invasive general surgery, the company said.
Hypersnam enables surgeons to assess tissue viability in real time during critical steps like bowel transection for cancer patients. The company hopes to bring its technology to laparoscopic, robotic, microscopic and endoscopic platforms in the future.
Michael Ebner, CEO and co-founder of Hypervision Surgical, said:
“This Series A marks a major milestone in our mission to power surgical intelligence through hyperspectral vision. By combining advanced spectral sensing with cloud-enabled AI analytics, we are building a new intelligence layer in surgery – giving surgeons real-time insights into tissue that were previously impossible to access.”
